REFRACTORY MANTLE CELL LYMPHOMA
Clinical trials for REFRACTORY MANTLE CELL LYMPHOMA explained in plain language.
Never miss a new study
Get alerted when new REFRACTORY MANTLE CELL LYMPHOMA trials appear
Sign up with your email to follow new studies for REFRACTORY MANTLE CELL LYMPHOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New combo therapy tested for aggressive lymphomas
Disease control CompletedThis early-stage trial tested a new combination of two immune-based drugs, lenalidomide and blinatumomab, for adults with non-Hodgkin lymphoma that has come back or stopped responding to other treatments. The main goal was to find the safest dose and understand the side effects. …
Matched conditions: REFRACTORY MANTLE CELL LYMPHOMA
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 30, 2026 14:28 UTC
-
New hope when CAR-T fails: experimental drug targets stubborn lymphoma
Disease control CompletedThis study tested an experimental drug called glofitamab for patients with aggressive lymphomas whose cancer returned or didn't respond after CAR-T cell therapy. The trial enrolled 67 patients across two groups with different lymphoma types. Researchers aimed to see if this new a…
Matched conditions: REFRACTORY MANTLE CELL LYMPHOMA
Phase: PHASE2 • Sponsor: The Lymphoma Academic Research Organisation • Aim: Disease control
Last updated Mar 25, 2026 14:08 UTC